Back to Dashboard








LABORATORIOS FARMACEUTICOS ROVI (ROVI.MC)
Real-time intraday values
Market Overview
From:
To:
ROVI.MC Intraday
No data available
SymbolROVI.MC
IPO DateDec 5, 2007
CEOMr. Juan Lopez-Belmonte Encina
Full Time Employees2k
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountrySpain
ExchangeMCE
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +0.33% | +0.20 US$ |
| 5 Days | +0.84% | +0.50 US$ |
| 1 Month | -25.65% | -20.80 US$ |
| 6 Months | +2.73% | +1.60 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ROVI.MC...
Key Statistics
Market Cap
3.09B
P/E Ratio
25.57
Div Yield
139.00%
52W High
$86.70
52W Low
$51.65
Analyst Consensus
CONSENSUSBuy
BULLISH555.6%
NEUTRAL444.4%
BEARISH00.0%
52W Analyst Price Targets
Min Target
$64.20
$64.20
Max Target
$90.00
$90.00
Current$60.35
Avg Target$76.49
Community Thoughts
Share your analysis and sentiment on ROVI.MC
Join the community to share your analysis
Latest News for ROVI.MC
Study reveals how offshore structures can help – or hinder – marine ecosystems
Energy Global•May 26, 2026, 02:00 PM
HaysMac appoints new director in Social Purpose team
International Accounting Bulletin•May 26, 2026, 01:57 PM
Interview: Chargebacks911 CEO Monica Eaton on post-sale blind spots costing merchants dearly
Electronic Payments•May 26, 2026, 01:57 PM
Chinese firms step up global expansion despite economic risks: report
The Accountant•May 26, 2026, 01:57 PM
H.B. Fuller Shareholder Ancora Opposes Proposed Acquisition of Advanced Medical Solutions
MT Newswires•May 26, 2026, 01:57 PM
AI is rewiring digital media’s power structure
Verdict•May 26, 2026, 01:57 PM
Two New Episodes of "Abundant Energy" and "Infinite Future" Explore the Infrastructure, Innovation, and Human Systems Shaping the AI Era
Business Wire•May 26, 2026, 01:57 PM

Stock market: How to be cautious while not overly bearish
Yahoo Finance Video•May 26, 2026, 01:56 PM
AGEL launches 3.37GWh BESS in Gujarat’s Khavda
Power Technology•May 26, 2026, 01:54 PM
Krombacher makes non-alc draught move
Just Drinks•May 26, 2026, 01:54 PM